Logo image of BOLT

BOLT BIOTHERAPEUTICS INC (BOLT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BOLT - US0977022039 - Common Stock

5.93 USD
+0.05 (+0.85%)
Last: 1/7/2026, 8:20:16 PM
Fundamental Rating

3

BOLT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. While BOLT seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, BOLT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BOLT has reported negative net income.
In the past year BOLT has reported a negative cash flow from operations.
In the past 5 years BOLT always reported negative net income.
BOLT had a negative operating cash flow in each of the past 5 years.
BOLT Yearly Net Income VS EBIT VS OCF VS FCFBOLT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -65.61%, BOLT is doing worse than 61.13% of the companies in the same industry.
BOLT has a worse Return On Equity (-132.96%) than 62.08% of its industry peers.
Industry RankSector Rank
ROA -65.61%
ROE -132.96%
ROIC N/A
ROA(3y)-48.44%
ROA(5y)-61.59%
ROE(3y)-74.37%
ROE(5y)-4101.17%
ROIC(3y)N/A
ROIC(5y)N/A
BOLT Yearly ROA, ROE, ROICBOLT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BOLT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BOLT Yearly Profit, Operating, Gross MarginsBOLT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

6

2. Health

2.1 Basic Checks

BOLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
BOLT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BOLT has been increased compared to 5 years ago.
There is no outstanding debt for BOLT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BOLT Yearly Shares OutstandingBOLT Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
BOLT Yearly Total Debt VS Total AssetsBOLT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -11.28, we must say that BOLT is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -11.28, BOLT is doing worse than 74.34% of the companies in the same industry.
There is no outstanding debt for BOLT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.28
ROIC/WACCN/A
WACC8.82%
BOLT Yearly LT Debt VS Equity VS FCFBOLT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

BOLT has a Current Ratio of 3.57. This indicates that BOLT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of BOLT (3.57) is comparable to the rest of the industry.
A Quick Ratio of 3.57 indicates that BOLT has no problem at all paying its short term obligations.
BOLT has a Quick ratio of 3.57. This is comparable to the rest of the industry: BOLT outperforms 44.72% of its industry peers.
Industry RankSector Rank
Current Ratio 3.57
Quick Ratio 3.57
BOLT Yearly Current Assets VS Current LiabilitesBOLT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

BOLT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.98%, which is quite impressive.
BOLT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -46.88%.
BOLT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 103.56% yearly.
EPS 1Y (TTM)32.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.5%
Revenue 1Y (TTM)-46.88%
Revenue growth 3Y82.75%
Revenue growth 5Y103.56%
Sales Q2Q%90.1%

3.2 Future

Based on estimates for the next years, BOLT will show a small growth in Earnings Per Share. The EPS will grow by 5.72% on average per year.
Based on estimates for the next years, BOLT will show a very strong growth in Revenue. The Revenue will grow by 24.13% on average per year.
EPS Next Y28.78%
EPS Next 2Y16.03%
EPS Next 3Y9.55%
EPS Next 5Y5.72%
Revenue Next Year-39.51%
Revenue Next 2Y-47.55%
Revenue Next 3Y-73.95%
Revenue Next 5Y24.13%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BOLT Yearly Revenue VS EstimatesBOLT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5M 10M 15M 20M 25M
BOLT Yearly EPS VS EstimatesBOLT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BOLT. In the last year negative earnings were reported.
Also next year BOLT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BOLT Price Earnings VS Forward Price EarningsBOLT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BOLT Per share dataBOLT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 -20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.03%
EPS Next 3Y9.55%

More info and screens

0

5. Dividend

5.1 Amount

BOLT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

BOLT BIOTHERAPEUTICS INC

NASDAQ:BOLT (1/7/2026, 8:20:16 PM)

5.93

+0.05 (+0.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-23 2026-03-23/amc
Inst Owners40.26%
Inst Owner Change0%
Ins Owners5.02%
Ins Owner Change1.4%
Market Cap11.39M
Revenue(TTM)5.20M
Net Income(TTM)-42.68M
Analysts76.36
Price Target27.29 (360.2%)
Short Float %0.12%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.6%
Min EPS beat(2)32.21%
Max EPS beat(2)36.99%
EPS beat(4)4
Avg EPS beat(4)23.18%
Min EPS beat(4)1.96%
Max EPS beat(4)36.99%
EPS beat(8)7
Avg EPS beat(8)17.25%
EPS beat(12)11
Avg EPS beat(12)15.33%
EPS beat(16)14
Avg EPS beat(16)13.74%
Revenue beat(2)2
Avg Revenue beat(2)154.53%
Min Revenue beat(2)115.75%
Max Revenue beat(2)193.31%
Revenue beat(4)3
Avg Revenue beat(4)66.29%
Min Revenue beat(4)-100%
Max Revenue beat(4)193.31%
Revenue beat(8)6
Avg Revenue beat(8)58.01%
Revenue beat(12)9
Avg Revenue beat(12)44.26%
Revenue beat(16)13
Avg Revenue beat(16)65.61%
PT rev (1m)0%
PT rev (3m)-20.54%
EPS NQ rev (1m)-42.02%
EPS NQ rev (3m)9.13%
EPS NY rev (1m)-13.02%
EPS NY rev (3m)11.02%
Revenue NQ rev (1m)-33.33%
Revenue NQ rev (3m)-13.04%
Revenue NY rev (1m)-17.2%
Revenue NY rev (3m)12.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.19
P/FCF N/A
P/OCF N/A
P/B 0.35
P/tB 0.35
EV/EBITDA N/A
EPS(TTM)-21.58
EYN/A
EPS(NY)-19.87
Fwd EYN/A
FCF(TTM)-24.58
FCFYN/A
OCF(TTM)-24.54
OCFYN/A
SpS2.71
BVpS16.72
TBVpS16.72
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -65.61%
ROE -132.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.44%
ROA(5y)-61.59%
ROE(3y)-74.37%
ROE(5y)-4101.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.92%
Cap/Sales 1.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.57
Quick Ratio 3.57
Altman-Z -11.28
F-Score2
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)43.39%
Cap/Depr(5y)172.25%
Cap/Sales(3y)12.39%
Cap/Sales(5y)328.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.5%
EPS Next Y28.78%
EPS Next 2Y16.03%
EPS Next 3Y9.55%
EPS Next 5Y5.72%
Revenue 1Y (TTM)-46.88%
Revenue growth 3Y82.75%
Revenue growth 5Y103.56%
Sales Q2Q%90.1%
Revenue Next Year-39.51%
Revenue Next 2Y-47.55%
Revenue Next 3Y-73.95%
Revenue Next 5Y24.13%
EBIT growth 1Y38.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-71.15%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y35.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.63%
OCF growth 3YN/A
OCF growth 5YN/A

BOLT BIOTHERAPEUTICS INC / BOLT FAQ

What is the ChartMill fundamental rating of BOLT BIOTHERAPEUTICS INC (BOLT) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BOLT.


Can you provide the valuation status for BOLT BIOTHERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to BOLT BIOTHERAPEUTICS INC (BOLT). This can be considered as Overvalued.


What is the profitability of BOLT stock?

BOLT BIOTHERAPEUTICS INC (BOLT) has a profitability rating of 0 / 10.


Can you provide the financial health for BOLT stock?

The financial health rating of BOLT BIOTHERAPEUTICS INC (BOLT) is 6 / 10.